Innovent starts China's first trial of a novel cancer immunotherapy - STAT

Innovent starts China's first trial of a novel cancer immunotherapy - STAT

STAT Plus: Innovent starts China’s first trial of a novel cancer immunotherapy

By JONATHAN CHAN

ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME

Innovent Biologics started an early-stage clinical trial for its monoclonal antibody IBI939, the first anti-TIGIT drug to be tested in China.

READ MORE